Home/Infinimmune/Mike Gibbons, PhD

MG

Mike Gibbons, PhD

Chief Scientific Officer & Co-Founder

Therapeutic Areas

Immunology Inflammation Dermatology Nephrology Gastroenterology

Infinimmune Pipeline

Drug	Indication	Phase
IFX-101	Moderate-to-Severe Atopic Dermatitis (msAD)	Preclinical
IFX-201	Moderate-to-Severe Atopic Dermatitis (msAD)	Preclinical
IFX-301	IgA Nephropathy (IgAN)	Preclinical
IFX-401	Ulcerative Colitis (UC)	Preclinical
IFX-501	Undisclosed	Undisclosed
Immunome Partnership	Undisclosed	Undisclosed

Leadership Team at Infinimmune

Wyatt McDonnell, PhD

CEO & Co-Founder

Katie Pfeiffer, PhD

Chief Technology Officer & Co-Founder

Tim Sullivan, PhD

Chief Business Officer

Lance Hepler, PhD

Chief Information Officer & Co-Founder

View full Infinimmune profile